- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03682068
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NILE)
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: AstraZeneca Clinical Study Information Center
- Phone Number: 1-877-240-9479
- Email: information.center@astrazeneca.com
Study Locations
-
-
-
Buenos Aires, Argentina, C1120AAT
- Research Site
-
Buenos Aires, Argentina, C1426ANZ
- Research Site
-
Ciudad de Buenos Aires, Argentina, 1280
- Research Site
-
Ciudad de Buenos Aires, Argentina, C1419AHL
- Research Site
-
Rosario, Argentina, S2000DEJ
- Research Site
-
-
-
-
-
Box Hill, Australia, 3128
- Research Site
-
Elizabeth Vale, Australia, 5112
- Research Site
-
Kogarah, Australia, 2217
- Research Site
-
Macquarie University, Australia, 2109
- Research Site
-
Murdoch, Australia, 6150
- Research Site
-
Orange, Australia, 2800
- Research Site
-
South Brisbane, Australia, 4101
- Research Site
-
St Albans, Australia, 3021
- Research Site
-
-
-
-
-
Curitiba, Brazil, 80810-050
- Research Site
-
Fortaleza, Brazil, 60336-232
- Research Site
-
Porto Alegre, Brazil, 90610-000
- Research Site
-
Porto Alegre, Brazil, 91350-200
- Research Site
-
Porto Alegre, Brazil, 90020-090
- Research Site
-
Ribeirão Preto, Brazil, 14048-900
- Research Site
-
Rio de Janeiro, Brazil, 22793-080
- Research Site
-
Rio de Janeiro, Brazil, 20231-050
- Research Site
-
Salvador, Brazil, 41.950-610
- Research Site
-
Santa Maria, Brazil, 97015-450
- Research Site
-
Sao Paulo, Brazil, 01327-001
- Research Site
-
São José do Rio Preto, Brazil, 15090-000
- Research Site
-
São Paulo, Brazil, 01246-000
- Research Site
-
-
-
-
-
Pleven, Bulgaria, 5800
- Research Site
-
Plovdiv, Bulgaria, 4000
- Research Site
-
Sofia, Bulgaria, 1431
- Research Site
-
Sofia, Bulgaria, 1527
- Research Site
-
Sofia, Bulgaria, 1797
- Research Site
-
Sofia, Bulgaria, 1303
- Research Site
-
Varna, Bulgaria, 9010
- Research Site
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N2
- Research Site
-
Edmonton, Alberta, Canada, T6G 1Z2
- Research Site
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- Research Site
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Research Site
-
Ottawa, Ontario, Canada, K1H 8L6
- Research Site
-
Toronto, Ontario, Canada, M5G IX6
- Research Site
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Research Site
-
-
-
-
-
Beijing, China, 100730
- Research Site
-
Beijing, China, 100034
- Research Site
-
Beijing, China, 100191
- Research Site
-
Changchun, China, 130021
- Research Site
-
Changsha, China, 410013
- Research Site
-
Changsha, China, 410008
- Research Site
-
Chongqing, China, 400038
- Research Site
-
Chongqing, China, 400042
- Research Site
-
Dalian, China, 116027
- Research Site
-
Guangzhou, China, 510000
- Research Site
-
Guangzhou, China, 510060
- Research Site
-
Hangzhou, China, 310022
- Research Site
-
Hangzhou, China, 310003
- Research Site
-
Hangzhou, China, 310009
- Research Site
-
Hangzhou, China, 310014
- Research Site
-
Jinan, China, 250012
- Research Site
-
Nanchang, China, 330006
- Research Site
-
Nanjing, China, 2100008
- Research Site
-
Shanghai, China, 200032
- Research Site
-
Shanghai, China, 200072
- Research Site
-
Shenyang, China, 110001
- Research Site
-
Suzhou, China, 215006
- Research Site
-
Tianjin, China
- Research Site
-
Tianjin, China, 300211
- Research Site
-
Urumqi, China, 830000
- Research Site
-
Wuhan, China, 430022
- Research Site
-
Xi'an, China, 710061
- Research Site
-
-
-
-
-
Brno, Czechia, 656 91
- Research Site
-
Hradec Kralove, Czechia, 500 05
- Research Site
-
Olomouc, Czechia, 77900
- Research Site
-
Ostrava, Czechia, 708 52
- Research Site
-
Praha, Czechia, 140 59
- Research Site
-
Praha 2, Czechia, 128 08
- Research Site
-
Praha 8, Czechia, 180 81
- Research Site
-
-
-
-
-
Budapest, Hungary, 1145
- Research Site
-
Budapest, Hungary, 1122
- Research Site
-
Budapest, Hungary, 1062
- Research Site
-
Debrecen, Hungary, 4032
- Research Site
-
Győr, Hungary, 9024
- Research Site
-
Kecskemét, Hungary, 6000
- Research Site
-
Szolnok, Hungary, 5000
- Research Site
-
-
-
-
-
Gurgaon, India, 122001
- Research Site
-
Hubli, India, 580025
- Research Site
-
Kolkata, India, 700160
- Research Site
-
Mysuru, India, 570017
- Research Site
-
Nagpur, India, 440012
- Research Site
-
Nasik, India, 422005
- Research Site
-
New Delhi, India, 110085
- Research Site
-
New Delhi, India, 11029
- Research Site
-
Pune, India, 411004
- Research Site
-
-
-
-
-
Haifa, Israel, 31096
- Research Site
-
Jerusalem, Israel, 91120
- Research Site
-
Kfar Saba, Israel, 95847
- Research Site
-
Petach-Tikva, Israel, 4941492
- Research Site
-
Ramat Gan, Israel, 52621
- Research Site
-
-
-
-
-
Arezzo, Italy, 52100
- Research Site
-
Milano, Italy, 20132
- Research Site
-
Milano, Italy, 20133
- Research Site
-
Napoli, Italy, 80131
- Research Site
-
Orbassano, Italy, 10043
- Research Site
-
Parma, Italy, 43126
- Research Site
-
Pavia, Italy, 27100
- Research Site
-
Roma, Italy, 00100
- Research Site
-
Terni, Italy, 05100
- Research Site
-
Verona, Italy, 37134
- Research Site
-
-
-
-
-
Bunkyo-ku, Japan, 113-8603
- Research Site
-
Chuo-ku, Japan, 104-0045
- Research Site
-
Fukuoka-shi, Japan, 811-1347
- Research Site
-
Hirosaki-shi, Japan, 036-8563
- Research Site
-
Kanazawa-shi, Japan, 920-8641
- Research Site
-
Kita-gun, Japan, 761-0793
- Research Site
-
Koshigaya-shi, Japan, 343-8555
- Research Site
-
Koto-ku, Japan, 135-8550
- Research Site
-
Kumamoto-shi, Japan, 860-0008
- Research Site
-
Kumamoto-shi, Japan, 860-8556
- Research Site
-
Kyoto-shi, Japan, 606-8507
- Research Site
-
Miyazaki-city, Japan, 889-1692
- Research Site
-
Nagasaki-shi, Japan, 852-8501
- Research Site
-
Nagoya-shi, Japan, 466-8560
- Research Site
-
Nagoya-shi, Japan, 467-0001
- Research Site
-
Niigata-shi, Japan, 951-8520
- Research Site
-
Osaka-shi, Japan, 541-8567
- Research Site
-
Osaka-shi, Japan, 545-8586
- Research Site
-
Osakasayama-shi, Japan, 589-8511
- Research Site
-
Shinjuku-ku, Japan, 160-8582
- Research Site
-
Suita-shi, Japan, 565-0871
- Research Site
-
Toyama-shi, Japan, 930-0194
- Research Site
-
Yokohama-shi, Japan, 241-8515
- Research Site
-
Yokohama-shi, Japan, 232-0024
- Research Site
-
-
-
-
-
Goyang-si, Korea, Republic of, 10408
- Research Site
-
Incheon, Korea, Republic of, 21565
- Research Site
-
Seoul, Korea, Republic of, 03722
- Research Site
-
Seoul, Korea, Republic of, 05505
- Research Site
-
Seoul, Korea, Republic of, 02841
- Research Site
-
Seoul, Korea, Republic of, 06351
- Research Site
-
Suwon, Korea, Republic of, 16247
- Research Site
-
-
-
-
-
Bacolod, Philippines, 6100
- Research Site
-
Baguio City, Philippines, 2600
- Research Site
-
Cebu, Philippines, 6000
- Research Site
-
Davao City, Philippines, 8000
- Research Site
-
Makati, Philippines, 1229
- Research Site
-
Manila, Philippines, 1015
- Research Site
-
Quezon City, Philippines, 1104
- Research Site
-
Quezon City, Philippines, 1101
- Research Site
-
-
-
-
-
Bialystok, Poland, 15-027
- Research Site
-
Gdańsk, Poland, 80-214
- Research Site
-
Grudziądz, Poland, 86-300
- Research Site
-
Koszalin, Poland, 75-581
- Research Site
-
Kraków, Poland, 31-501
- Research Site
-
Olsztyn, Poland, 10-228
- Research Site
-
Poznan, Poland, 60-693
- Research Site
-
Radom, Poland, 26-600
- Research Site
-
Warszawa, Poland, 02-781
- Research Site
-
-
-
-
-
Ivanovo, Russian Federation, 153040
- Research Site
-
Krasnoyarsk, Russian Federation, 660133
- Research Site
-
Moscow, Russian Federation, 125284
- Research Site
-
Moscow, Russian Federation, 105229
- Research Site
-
Moscow, Russian Federation, 115280
- Research Site
-
Moscow, Russian Federation, 105077
- Research Site
-
Nizhniy Novgorod, Russian Federation, 603074
- Research Site
-
Nizhniy Novgorod, Russian Federation, 603137
- Research Site
-
Omsk, Russian Federation, 644013
- Research Site
-
Rostov-on-Don, Russian Federation, 344037
- Research Site
-
Saint-Petersburg, Russian Federation, 195067
- Research Site
-
St. Petersburg, Russian Federation, 197758
- Research Site
-
St. Petersburg, Russian Federation, 199178
- Research Site
-
Tyumen, Russian Federation, 625041
- Research Site
-
Vologda, Russian Federation, 160012
- Research Site
-
-
-
-
-
Barcelona, Spain, 8035
- Research Site
-
Barcelona, Spain, 08908
- Research Site
-
Barcelona, Spain, 8003
- Research Site
-
Lugo, Spain, 27003
- Research Site
-
Madrid, Spain, 28034
- Research Site
-
Madrid, Spain, 28040
- Research Site
-
Madrid, Spain, 28007
- Research Site
-
Malaga, Spain, 29010
- Research Site
-
Santander, Spain, 39008
- Research Site
-
Sevilla, Spain, 41013
- Research Site
-
-
-
-
-
Taichung, Taiwan, 40705
- Research Site
-
Taichung, Taiwan, 404
- Research Site
-
Tainan, Taiwan, 704
- Research Site
-
Taipei, Taiwan, 11217
- Research Site
-
Taipei City, Taiwan, 10050
- Research Site
-
Taoyuan, Taiwan, 333
- Research Site
-
-
-
-
-
Bangkok, Thailand, 10300
- Research Site
-
Bangkok, Thailand, 10400
- Research Site
-
Khon Kaen, Thailand, 40002
- Research Site
-
Mueang, Thailand, 50200
- Research Site
-
Songkla, Thailand, 90110
- Research Site
-
-
-
-
-
Adana, Turkey, 1260
- Research Site
-
Adapazari, Turkey, 54290
- Research Site
-
Ankara, Turkey, 06590
- Research Site
-
Edirne, Turkey, 22030
- Research Site
-
Istanbul, Turkey, 34030
- Research Site
-
Izmir, Turkey
- Research Site
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Research Site
-
-
California
-
Bakersfield, California, United States, 93309
- Research Site
-
Fullerton, California, United States, 92835
- Research Site
-
Los Angeles, California, United States, 90095
- Research Site
-
Salinas, California, United States, 93901
- Research Site
-
Santa Barbara, California, United States, 93105
- Research Site
-
Truckee, California, United States, 96161
- Research Site
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Research Site
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Research Site
-
-
Florida
-
Orlando, Florida, United States, 32806
- Research Site
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Research Site
-
-
Indiana
-
Fort Wayne, Indiana, United States, 46804
- Research Site
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- Research Site
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Research Site
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Research Site
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49503
- Research Site
-
-
Montana
-
Bozeman, Montana, United States, 59715
- Research Site
-
-
New York
-
New Hyde Park, New York, United States, 11042
- Research Site
-
New York, New York, United States, 10065
- Research Site
-
New York, New York, United States, 10029
- Research Site
-
Rochester, New York, United States, 14642
- Research Site
-
-
Tennessee
-
Germantown, Tennessee, United States, 38138
- Research Site
-
-
Texas
-
Fort Worth, Texas, United States, 76104
- Research Site
-
-
-
-
-
Ha Noi, Vietnam, 100000
- Research Site
-
Hanoi, Vietnam, 100000
- Research Site
-
Hanoi, Vietnam, 10000
- Research Site
-
Ho Chi Minh, Vietnam, 70000
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Patients with histologically or cytologically documented, unresectable, locally advanced or metastatic transitional cell carcinoma (transitional cell and mixed transitional/non-transitional cell histologies) of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra)
- Patients who have not been previously treated with first-line chemotherapy. Patients who have received prior definitive chemoradiation, adjuvant or neoadjuvant treatment for locally advanced disease are eligible provided that progression to locally advanced or metastatic disease has occurred >12 months from the last therapy [for chemoradiation and adjuvant treatment] or >12 months from the last surgery [for neoadjuvant treatment].
- At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 target lesion at baseline.
- World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at enrolment
- Adequate organ and marrow function as defined in the protocol
- Life expectancy ≥12 weeks in the opinion of the investigator
- Evidence of post-menopausal status, or negative urinary or serum pregnancy test for female pre-menopausal patients.
Key Exclusion Criteria:
- Prior exposure to immune-mediated therapy (with exclusion of Bacillus Calmette Guerin), including but not limited to, other anti-CTLA-4, anti-PD-1, anti-PD L1, or anti-PD-L2 antibodies, except therapeutic anticancer vaccines, which are permitted. Prior local intervesical chemotherapy or immunotherapy is allowed if completed at least 28 days prior to the initiation of study treatment.
- No severe concomitant condition that requires immunosuppression medication
- Untreated central nervous system (CNS) metastases and/or carcinomatous meningitis
- Patients who may be eligible for or are being considered for radical resection during the course of the study.
- Any medical contraindications to platinum (cisplatin or carboplatin) based doublet chemotherapy and/or known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Durvalumab in Combination with SoC Chemotherapy
Durvalumab every 3 weeks in concurrence with chemotherapy, followed by durvalumab monotherapy every 4 weeks. All patients will receive one of the following standard of care chemotherapy regimens every 3 weeks for 6 cycles:
|
Durvalumab IV (intravenous infusion)
Other Names:
Cisplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
Carboplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
|
Experimental: Durvalumab in Combination with Tremelimumab+SoC Chemotherapy
Durvalumab and Tremelimumab every 3 weeks in concurrence with chemotherapy, followed by durvalumab monotherapy every 4 weeks Tremelimumab will be provided for 4 cycles. All patients will receive one of the following standard of care chemotherapy regimens every 3 weeks for 6 cycles:
|
Durvalumab IV (intravenous infusion)
Other Names:
Tremelimumab IV (intravenous infusion)
Cisplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
Carboplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
|
Active Comparator: SoC Chemotherapy
Patients will receive one of the following standard of care chemotherapy regimens every 3 weeks for 6 cycles:
|
Cisplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
Carboplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: approximately 5 years
|
OS is defined as the time from the date of randomization until death due to any cause
|
approximately 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: approximately 5 years
|
Additional analysis beyond the primary endpoint
|
approximately 5 years
|
Overall Survival at 24 months (OS24)
Time Frame: 24 months
|
The OS24 will be defined as the Kaplan-Meier estimate of OS at 24 months
|
24 months
|
Progression Free Survival (PFS)
Time Frame: approximately 5 years
|
PFS (per RECIST 1.1) will be defined as the time from the date of randomization until the date of first objective disease progression or death
|
approximately 5 years
|
Alive and Progression Free Survival at 12 months (APF12)
Time Frame: 12 months
|
The APF12 will be defined as the Kaplan-Meier estimate of PFS (per RECIST 1.1) at 12 months
|
12 months
|
Objective Response Rate (ORR)
Time Frame: approximately 5 years
|
ORR (per RECIST 1.1) is defined as the number (%) of patients with at least 1 visit response of complete response or partial response and will be based on a subset of all randomized patients
|
approximately 5 years
|
Duration of Response (DoR)
Time Frame: approximately 5 years
|
DoR (per RECIST 1.1) will be defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression
|
approximately 5 years
|
Disease Control Rate (DCR)
Time Frame: approximately 5 years
|
DCR is defined as the proportion of subjects with the best overall response of complete response, partial response or stable disease per RECIST 1.1
|
approximately 5 years
|
Time from randomization to second (PFS2)
Time Frame: approximately 5 years
|
PFS2 will be defined as the time from the date of randomization to the earliest of the progression events subsequent to that used for the PFS endpoint or death
|
approximately 5 years
|
To assess disease-related symptoms, physical functioning, and other Health-related quality of life
Time Frame: approximately 5 years
|
Collection of patient reported outcome questionnaires
|
approximately 5 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess safety using a summary of adverse events.
Time Frame: approximately 5 years
|
Adverse Events (both in terms of MedDRA preferred terms and CTCAE grade) will be listed individually by patient.
The number of patients experiencing each Adverse Event will be summarized by treatment arm and CTCAE grade
|
approximately 5 years
|
To assess pharmacokinetics of Durvalumab and Tremelimumab
Time Frame: approximately 5 years
|
Serum concentrations of Durvalumab and Tremelimumab
|
approximately 5 years
|
To assess immunogenicity of Durvalumab and Tremelimumab
Time Frame: approximately 5 years
|
Presence of anti-drug antibodies for Durvalumab and Tremelimumab
|
approximately 5 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D933SC00001
- 2018-001883-48 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Urothelial Cancer
-
Gilead SciencesMerck KGaA, Darmstadt, GermanyRecruitingMetastatic Urothelial CancerItaly, United States, Korea, Republic of, Spain, Greece, France, Germany, United Kingdom, Turkey
-
Matthew GalskyBristol-Myers Squibb; Hoosier Cancer Research NetworkActive, not recruitingMetastatic Urothelial CancerUnited States
-
Astellas Pharma Global Development, Inc.Seagen Inc.CompletedMetastatic Urothelial CancerUnited States, Canada
-
Ectin Research ABNot yet recruitingMetastatic Urothelial CancerSweden
-
Matthew GalskyIcahn School of Medicine at Mount Sinai; AstraZenecaCompletedMetastatic Urothelial CancerUnited States
-
University Hospital, GhentCompletedMetastatic Urothelial CancerBelgium
-
Monika Joshi, MDPfizer; Eisai Inc.; Big Ten Cancer Research ConsortiumTerminatedMetastatic Urothelial Cell CancerUnited States
-
Gilead SciencesEverest MedicinesActive, not recruitingLocally Advanced or Metastatic Unresectable Urothelial CancerUnited States, Belgium, France, Spain, United Kingdom, Korea, Republic of, Czechia, Germany, Israel, China, Italy, Australia, Hong Kong, Taiwan, Portugal, Singapore, Croatia, Greece, Turkey, Sweden, Switzerland, Canada, Austria, Bulgaria and more
-
National Cancer Institute (NCI)CompletedMetastatic Prostate Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage IV Renal... and other conditionsUnited States, Puerto Rico
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditionsUnited States
Clinical Trials on Durvalumab
-
AstraZenecaKappa SantéRecruiting
-
Yonsei UniversityRecruitingPotentially Resectable Stage II/IIIa NSCLCKorea, Republic of
-
Academic Thoracic Oncology Medical Investigators...AstraZenecaCompletedNon-Small Cell Lung Cancer NSCLCUnited States
-
Yonsei UniversityCompleted
-
NSABP Foundation IncCompletedRectal CancerUnited States
-
Hark Kyun KimRecruiting
-
Oslo University HospitalAstraZenecaActive, not recruitingCancer | NSCLC | Non Small Cell Lung Cancer | NSCLC, Stage III | Non Small Cell Lung Cancer Stage IIINorway, Finland, Lithuania, Estonia
-
MedImmune LLCCompletedAdvanced Solid TumorsUnited States, France, Spain, Switzerland
-
MedImmune LLCCompletedStage III Non-small Cell Lung Cancer | UnresectableUnited States, Canada, Italy, Spain, France, Hong Kong, Portugal, Taiwan, Poland
-
AstraZenecaCompleted